PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Sickle cell disease - Market size and forecast 2018-2023 • Thalassemia - Market size and forecast 2018-2023 • Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • Americas - Market size and forecast 2018-2023 • EMEA - Market size and forecast 2018-2023 • APAC - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DRIVERS AND CHALLENGES PART 10: VENDOR LANDSCAPE • Market drivers • Market challenges PART 11: MARKET TRENDS PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • ApoPharma • Bristol-Myers Squibb • Emmaus Medical • Medunik USA • Novartis PART 14: APPENDIX • Research methodology • List of abbreviations Exhibit 01: Years in consideration Exhibit 02: Global hematology drugs market Exhibit 03: Segments of global hematology drugs market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Type - Market share 2018-2023 (%) Exhibit 19: Comparison by type Exhibit 20: Sickle cell disease - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Sickle cell disease - Year-over-year growth 2019-2023 (%) Exhibit 22: Thalassemia - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Thalassemia - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by type Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions) Exhibit 29: Americas - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in Americas Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ millions) Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in EMEA Exhibit 34: APAC - Market size and forecast 2018-2023 ($ millions) Exhibit 35: APAC - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in APAC Exhibit 37: Key leading countries Exhibit 38: Market opportunity Exhibit 39: Decision framework Exhibit 40: Therapeutics that have received the orphan drug designation from the US FDA recently Exhibit 41: Impact of drivers and challenges Exhibit 42: Vendor landscape Exhibit 43: Landscape disruption Exhibit 44: Vendors covered Exhibit 45: Vendor classification Exhibit 46: Market positioning of vendors Exhibit 47: ApoPharma - Vendor overview Exhibit 48: ApoPharma - Business segments Exhibit 49: ApoPharma - Organizational developments Exhibit 50: ApoPharma - Key offerings Exhibit 51: ApoPharma - Key customers Exhibit 52: Bristol-Myers Squibb - Vendor overview Exhibit 53: Bristol-Myers Squibb - Business segments Exhibit 54: Bristol-Myers Squibb - Organizational developments Exhibit 55: Bristol-Myers Squibb - Geographic focus Exhibit 56: Bristol-Myers Squibb - Key offerings Exhibit 57: Bristol-Myers Squibb - Key customers Exhibit 58: Emmaus Medical - Vendor overview Exhibit 59: Emmaus Medical - Business segments Exhibit 60: Emmaus Medical - Organizational developments Exhibit 61: Emmaus Medical - Geographic focus Exhibit 62: Emmaus Medical - Key offerings Exhibit 63: Emmaus Medical - Key customers Exhibit 64: Medunik USA - Vendor overview Exhibit 65: Medunik USA - Business segments Exhibit 66: Medunik USA - Organizational developments Exhibit 67: Medunik USA - Key offerings Exhibit 68: Medunik USA - Key customers Exhibit 69: Novartis - Vendor overview Exhibit 70: Novartis - Business segments Exhibit 71: Novartis - Organizational developments Exhibit 72: Novartis - Geographic focus Exhibit 73: Novartis - Segment focus Exhibit 74: Novartis - Key offerings Exhibit 75: Novartis - Key customers Exhibit 76: Validation techniques employed for market sizing Exhibit 77: List of abbreviations  

ApoPharma Bristol-Myers Squibb Emmaus Medical Medunik USA Novartis